NAD precursor detection model

What this model does

This is a coaching and interpretation model for NMN/NR use, not a diagnostic model and not a wearable-only detector.

It helps Vitals decide whether NAD+ precursor use is plausible, whether a user is a reasonable candidate for monotherapy, and whether claimed benefits should be accepted or rejected.

Core boundary: wearables cannot detect NAD+ elevation directly. Blood NAD+ can support exposure, but even blood NAD+ does not prove tissue NAD+ delivery or clinical benefit.

Input requirements

High-value inputs:

• age and goal context
• baseline health status and medications
• supplement log: NMN vs NR, dose, route, timing, brand, third-party testing if available
• baseline and follow-up blood NAD+ if available
• safety labs when clinically appropriate: liver enzymes, triglycerides, homocysteine context
• training load, illness, alcohol, sleep debt, calorie deficit, and medication changes

Optional / weak inputs:

• HRV / RMSSD trend
• resting heart rate trend
• sleep duration and sleep regularity
• CGM context if metabolic goals are present
• subjective energy / fatigue reports

Core decision logic

def nad_precursor_interpretation(client):
    """
    Conservative BATCH161-derived logic.
    This model rejects stacking claims unless future human co-administration evidence exists.
    """
 
    if client.requesting_nmn_nr_stack:
        return {
            "recommendation": "do_not_default_to_stack",
            "reason": "No published human NMN+NR co-administration RCT exists",
            "confidence": "high",
            "claim_allowed": "NMN or NR monotherapy can raise blood NAD+; stacking superiority is unproven"
        }
 
    if client.goal in ["muscle_gain", "athletic_performance", "vo2max", "longevity_extension"]:
        return {
            "recommendation": "do_not_position_as_primary_intervention",
            "reason": "Blood NAD+ elevation does not prove muscle NAD+ elevation or functional benefit",
            "confidence": "moderate_to_high",
            "better_anchor": "exercise / training / sleep / nutrition"
        }
 
    if client.age >= 50 and client.blood_nad_low:
        return {
            "recommendation": "consider_single_precursor_trial_with_monitoring",
            "reason": "Older adult with low measured NAD+ is the most plausible candidate profile",
            "confidence": "moderate",
            "stacking": "not_supported"
        }
 
    return {
        "recommendation": "insufficient_reason_to_recommend",
        "reason": "No demonstrated functional benefit in healthy adults",
        "confidence": "moderate"
    }

Features that matter

Feature	Interpretation value	Notes
Blood NAD+ baseline and follow-up	Moderate	Best available exposure marker; not tissue or outcome proof.
Age / baseline NAD+ status	Moderate	Older, low-NAD+ users are more plausible candidates than young healthy users.
Goal context	High	Muscle, longevity, and broad energy claims are where marketing most often exceeds evidence.
Dose and route	Moderate	Oral NMN/NR evidence exists; sublingual/liposomal superiority is not established.
Product quality	High	Incorrect active ingredient amounts have been documented commercially.
HRV / RHR	Low	Useful only as non-specific context, not as NAD+ detection.
Sleep / readiness	Low	Confounded by behavior, illness, stress, and training load.
CGM metrics	Low-contextual	NAD+ precursors are not established glucose-lowering tools for the general population.

Features that mislead

• Early subjective energy changes before a stable dosing window.
• Single-day HRV or readiness improvements.
• Blood NAD+ increases treated as proof of skeletal-muscle benefit.
• Claims that NMN+NR is automatically additive because the compounds are different precursors.
• Sublingual or liposomal marketing framed as proven human superiority.
• Improvements during simultaneous changes in exercise, alcohol, sleep, calorie intake, GLP-1 therapy, or stimulant use.

Timing caveats

• Blood NAD+ changes generally require consistent dosing over days to weeks.
• The source document uses roughly 1–2 weeks for NR steady-state and 2–4 weeks for NMN steady-state as practical expectations.
• Wearable changes, if any, should be evaluated only after controlling for training load, sleep, illness, alcohol, medication changes, and calorie balance.
• Long-term interpretation is limited because source-backed safety windows are short: about 12 weeks for NMN and 5 months for NR.

Route / formulation caveats

Route / formulation	Evidence boundary
Oral capsule	Main human evidence base.
Sublingual NMN	No peer-reviewed human trial in the source corpus proves superior bioavailability vs oral.
Liposomal NAD+ precursors	Mechanistically plausible but not demonstrated in humans in the source corpus.
NMN + NR co-administration	No published human RCT; stacking benefit and safety are unknown.

Confidence levels

Question	Confidence	Answer
Can NMN or NR raise blood NAD+?	Moderate–high	Yes, as monotherapy.
Can wearables detect NAD+ elevation?	Low	No validated wearable signature.
Does blood NAD+ prove skeletal-muscle NAD+?	Low	No; source corpus says this does not reliably translate.
Is NMN+NR stacking superior to monotherapy?	Very low	No human co-administration trial.
Can Vitals coach against overclaims?	High	Yes: reject additive, muscle, longevity, and disease-modification claims without stronger evidence.

What this model cannot detect

• Tissue NAD+ elevation in skeletal muscle, brain, or liver.
• Sirtuin activation in a clinically meaningful way.
• Longevity benefit.
• Disease modification.
• Whether NMN+NR is additive or synergistic.
• Whether a commercial product contains the labeled active dose.

Related notes

• NAD Precursor Stacking — evidence boundary and practical protocol
• NAD+ Salvage Pathway — mechanism
• NMN NAD+ — broader precursor monograph
• HRV — non-specific recovery marker
• Cardiovascular signatures — RHR/HRV/BP context
• Glucose Variability Detection Model — metabolic context and CGM limitations